Awareness of breast cancer incidence and risk factors among healthy women

European Journal of Cancer Prevention

Volumn 13, Issue 4, 2004, Pages 249-256

  Pohls U G ^a   Renner, S P ^a   Fasching, P A ^a   Lux, M P ^a   Kreis, H ^a   Ackermann, S ^a   Bender, H G ^b   Beckmann, M W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Breast cancer; Cancer detection programs; Incidence; Risk factor awareness in healthy women

Indexed keywords

CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AWARENESS; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; COMPREHENSION; CONTROLLED STUDY; EDUCATION; FAMILY HISTORY; FEMALE; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; LIFESPAN; MEDICAL INFORMATION; MENARCHE; MENOPAUSE; PERCEPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SCIENCE; SOCIAL STATUS; SOCIOECONOMICS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ATTITUDE TO HEALTH; AWARENESS; BREAST NEOPLASMS; FEMALE; GERMANY; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PATIENT COMPLIANCE; PRIMARY PREVENTION; PROBABILITY; QUESTIONNAIRES; REFERENCE VALUES; RISK FACTORS;

EID: 4143120358     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000136718.03089.a5     Document Type: Article

References (32)

1. ATAC Trialists' Group (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139.
2. Beckmann MW, Niederacher D, Goecke TO, Bodden-Heidrich R, Schnürch HG, Bender HG (1997). High risk families with breast and ovary cancer [Hochrisikofamilien mit Mamma- und Ovarialkarzinomen], Dt Ärztebl 94: A161-A167.
3. Beckmann MW, Niederacher D, Bodden-Heidrich R, Goeoke TO, Kuschel B, Achnoula M, Aba F, Schnurch HG, Bender HG (1998). [Tumor risk consultation for predisposed women from high risk cancer families], Schweiz Rundsch. Med Prax 87: 511-515.
4. Beckmann MW, Untch M, Rabe T, Schulz KD, Bender HG (1999). Chemoprevention of breast cancer [(Chemo) Praevention des Mammakarzinoms]. Gynäkologe 32: 150-157.
5. Beckmann MW, Werner Y, Renner SP, Jap D, Kuschel B (2000). Early cancer detection in gynaecological practice - recent aspects of scientific discussions [Krebsfrüherkennung in der frauenärztlichen Praxis - Aktuelle Aspekte der wissenschaftlichen Diskussion], Gynäkologe 30: 474-482.
6. Beckmann MW, Fasching PA, Weiss JM, Magener A, Ortmann O (2003a). Update on primary breast cancer 2003 [Update primäres Mammakarzinom 2003]. Geburtsh Frauenheilk 63: R65-R92.
7. Beckmann MW, Braendle W, Brucker C, et al. (2003b). Hormone therapy in climactere and postmenopausal woman - a consensus of the DGGG [Konsensusempfehlungen zur Hormontherapie (HT) im Klimakterium und in der Postmenopause]. Geburtsh Frauenheilk 63: 209-212.
8. Chlebowski RT, Hendrix SL, Langer RD, et al., WHI Investigators (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289: 3243-3253.
9. Collaborative Group on Hormonal Factors in Breast Cancer (1997). Breast cancer and hormonal contraceptives: collaborative analysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350: 1047-1059.
10. Collaborative Group on Hormonal Factors in Breast Cancer (2000). Contraceptive methods and breast cancer risk: an update. Contracept Rep 11: 9-11.
11. Coleman EA, O'Sullivan P (2001). Racial differences in breast cancer screening among women from 65 to 74 years of age: trends from 1987-1993 and barriers to screening. J Women Aging 13: 23-39.
12. Freeman AG, Scott C, Waxman A, Arcona S (2000). What do adolescent females know about breast cancer and prevention? J Pediatr Adolesc Gynecol 13: 96.
13. Fylan F (1998). Screening for cervical cancer: a review of women's attitudes, knowledge, and behaviour. Br J Gen Pract 48: 1509-1514.
14. Glaus A, Castiglione M (2001). Women and cancer - result of a Swiss survey in patients with breast or gynaecological cancer [Frauen und Krebs-Resultate der Umfrage bei Schweizer Patientinnen mit Brustkrebs oder einem gynäkologischen Tumor], im Internet: http://www.swisscancer.ch/cawac/ editoral/index2-de.html
15. Hulley S, Furberg C, Barrett-Connor E, et al. (2002). Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 58-66.
16. Kaufmann M, Ernst B (2000). What women with cancer are experiencing, perceiving, knowing and missing [Was Frauen mit Krebs erfahren, empfinden, wissen und vermissen]. Dt Ärztebl 97: A3191-A3196.
17. Köohli OR, Sevin BU, Benz J, Petru E, Haller U (1998). Gynäkologische Onkologie: Manual für Klinik und Praxis. 2. Aufl., Heidelberg, New York: Springer-Verlag, Berlin.
18. Kuschel B, Aba F, Lux M, et al. (2000a). Breast cancer: evaluation of individual risks and prevention possibilities [Mammakarzinom: Ermittlung des individuellen Erkrankungsrisikos und Möglichkeiten der Prävention], Z ärztl Fortbild Qual 94: 231-237.
19. Kuschel B, Köchli OR, Niederacher D, Müller HJ, Beckmann MW (2000b). Inherited cancer syndromes - what should the practitioner knowl [Hereditäre Karzinomsyndrome in der Frauenheilkunde - was der Praktiker wissen solltel] Schweiz Med Wochenschr 130: 362-375.
20. Metsch LR, McCoy C, McCoy HV, et al. (1998). The role of the physician as an information source on mammography. Cancer Pract 6: 229-236.
21. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS (1991). Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83: 1450-1459.
22. Osborne CK (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618.
23. Paepke S, Schubert R, Hüttner C, Blohmer JU, Lichtenegger W (2000). Awareness and preventional behaviour of the female population of Berlin and Hildesheim, Germany regarding breast cancer - results of a cross-sectional study of 2110 women [Informiertheit und Brustkrebsvorsorgeverhalten der weiblichen Bevölkerung in Berlin und Hildesheim-Ergebnisse einer Querschnittsuntersuchung von 2110 Frauen]. Geb Fra 60: 620-624.
24. Paepke S, Schwarz-Boeger U, von Minckwitz G, et al. (2001). Early Breast cancer detection [Brustkrebsfrüherkennung]. Dt Aerztebl 98: 2178-2186.
25. Paul C, Barratt A, Redman S, Cockburn J, Lowe J (1999). Knowledge and perceptions about breast cancer incidence, fatality and risk among Australian women. Aust N Z J Public Health 23: 396-400.
26. Rees CE, Bath PA (2000). The information needs and source preferences of women with breast cancer and their family members. A review of the literature published between 1988 and 1998. J Adv Nurs 31: 833-841.
27. Rees CE, Bath PA (2001). Information-seeking behaviors of women with breast cancer. Oncol Nurs Forum 5: 899-907.
28. Rossouw JE, Anderson GL, Prentice RL, et al., Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
29. Rutledge DN, Barsevick A, Knobf MT, Bookbinder M (2001). Breast cancer detection: knowledge, attitudes, and behaviors of women from Pennsylvania. Oncol Nurs Forum 6: 1032-1040.
30. Serin D, Pujoi H, Schraub S, Chevalier H (1998). Parcours de femmes. Opinion survey carried out among women treated for gynecologic and breast cancers and their medical care teams. Bull Cancer 85: 578-588.
31. Veronesi U, von Kleist S, Redmond K, et al. (1999). Caring About Women and Cancer (CAWAC): a European survey of the perspectives and experiences of women with female cancers. Eur J Cancer 35: 1667-1675.
32. Wooster R, Weber BL (2003). Breast and ovarian cancer. N Engl J Med 348: 2339-2347.